A double-blind, randomized, multicenter, placebo-controlled, parallel-group phase IV clinical trial to assess the efficacy of pancreatic enzyme replacement therapy (PERT) in patients with pancreatic exocrine insufficiency (PEI) secondary to type 1 diabetes mellitus (DM).
Phase of Trial: Phase IV
Latest Information Update: 02 Jan 2014
At a glance
- Drugs Pancrelipase (Primary)
- Indications Exocrine pancreatic insufficiency
- Focus Therapeutic Use
- 02 Jan 2014 New trial record